Experience with the use of nivolumab and ipilimumab in metastatic fibrolamellar liver carcinoma

Abstract

Fibrolamellar hepatocellular carcinoma is a rare primary liver tumor with no known risk factors, which occurs in 1–7% of cases of all hepatocellular carcinoma. The disease occurs mainly in adolescents, as an accidental finding or when symptoms appear already during the metastatic process. The main method of treatment with proven efficacy for localized fibrolamellar hepatocellular carcinoma is surgical. The experience of using radiation therapy and transarterial chemoembolization is contradictory and needs additional study. The option of preferred drug antitumor treatment is not fully clear, and the search for effective therapy regimens and potential targets specific to this form of hepatocellular carcinoma is relevant and requires further study. Considering the rarity of the pathology, the world literature presents data on the treatment of small groups of patients and clinical cases of successful use of a number of medicinal antitumor regimens. However, the data are contradictory. The literature describes isolated clinical cases of successful use of immunotherapy in patients with fibrolamellar hepatocellular carcinoma, requiring further detailed study. Using the example of this clinical case, we have shown the successful long-term use of combined immunotherapy in a patient with fibrolamellar liver carcinoma.